Clinical Edge Journal Scan

Ultrasound helps screen patients with moderate-to-severe psoriasis progressing to subclinical PsA


 

Key clinical point: In patients with moderate-to-severe psoriasis, the presence of synovio-enthesitis on ultrasound, particularly in lower limbs, indicated progression to subclinical psoriatic arthritis (PsA). Therefore, routine ultrasound screening should be performed irrespective of arthritis symptoms.

Major finding: Only synovio-enthesitis diagnosis differed significantly among patients with silent psoriasis vs control individuals (16.1% vs 1.3%; P < .001), with 12.7% of patients diagnosed with synovio-enthesitis progressing to subclinical PsA and the top four sites with synovio-enthesitis involvement being in lower limbs. Body surface area and Psoriasis Area and Severity Index scores were not different in psoriasis, subclinical PsA, and prodromal/active PsA phases.

Study details: This cross-sectional study included 490 patients with moderate-to-severe psoriasis, of which 384 and 106 patients without and with arthritis symptoms formed the silent psoriasis and clinical PsA groups, respectively, and 80 age- and sex-matched control individuals without psoriasis.

Disclosures: This study was supported by the National Natural Science Foundation of China and other sources. The authors declared no conflicts of interest.

Source: Chen ZT et al. The role of ultrasound in screening subclinical psoriatic arthritis in patients with moderate to severe psoriasis. Eur Radiol . 2023 (Feb 28). Doi: 10.1007/s00330-023-09493-4

Recommended Reading

Isolated nail psoriasis may bring arthritis into play
MDedge Rheumatology
Commentary: Concerning PsA treatments and comorbidities, March 2023
MDedge Rheumatology
Biologics show signs of delaying arthritis in psoriasis patients
MDedge Rheumatology
Psoriatic arthritis treatment for women falls short, study suggests
MDedge Rheumatology
Gender-based differences in treatment outcomes and persistence with ustekinumab or TNFi in PsA
MDedge Rheumatology
Achievement of low disease activity improves long-term structural damage in PsA
MDedge Rheumatology
Active disease in third trimester increases risk for emergency caesarean section in PsA
MDedge Rheumatology
Guselkumab resolves dactylitis and improves clinical outcomes in patients with active PsA
MDedge Rheumatology
JAKi effective for PsA but higher doses may have increased toxicity
MDedge Rheumatology
Real world study finds no evidence of increased cancer risk with JAKi vs TNFi in PsA
MDedge Rheumatology